Hunt for Malaria Vaccine Raises a Storm: Malaria Kills More People in Africa Than HIV-Aids. Therefore Attempts to Produce a Vaccine against the Disease Should Normally Be Received with Joy. but No. the Trial Stages of a New Vaccine, RTS, S, Have Raised a Storm in Africa. Our Kenyan Correspondent, Wanjohi Kabukuru, Went to Find Out

By Kabukuru, Wanjohi | New African, October 2011 | Go to article overview

Hunt for Malaria Vaccine Raises a Storm: Malaria Kills More People in Africa Than HIV-Aids. Therefore Attempts to Produce a Vaccine against the Disease Should Normally Be Received with Joy. but No. the Trial Stages of a New Vaccine, RTS, S, Have Raised a Storm in Africa. Our Kenyan Correspondent, Wanjohi Kabukuru, Went to Find Out


Kabukuru, Wanjohi, New African


PINGILIKANI IS A SMALL VILLAGE in Chonyi, deep in Kilifi County, in Kenya's coastal region. Just like its Swahili name suggests, it is a place of stunning rolling hills and steep undulating knolls.

It is at Pingilikani that Felicia Dzombo's daughter took part in history-making. Dzombo's daughter is among 15,460 infants and children drawn from seven African countries who have been enrolled in the testing of a potential malaria vaccine, called RTS, S. According to the World Health Organisation (WHO), over one million people die annually from malaria, the majority of them in 3o sub-Saharan African countries. Malaria is also the leading cause of death for children under five.

The annual economic cost of the disease currently stands at sizbn. Over the years, Dzombo has seen several trials within her immediate family and community but she does not know what happens after the tests.

At the Pingilikani Health Dispensary, three heavyweight institutions--GlaxoSmithKline Biologicals (GSK Biologicals), PATH Malaria Vaccine Initiative (PATHMVI), and the Kenya Medical Research Institute (KEMRI), the country's principal medical research agency, among other partners--have set up a malaria vaccine trial site.

Pingilikani is one of II such trial sites spread across seven African countries. The others are in Nanoro (Burkina Faso), Lambarene. (Gabon), Kintampo and Kumasi (Ghana), Lilongwe, (Malawi), Manhica (Mozambique), Bagamoyo and Korogwe (Tanzania) and Siaya, Kombewa and Kilifi (Kenya). The trial sites were strategically picked as they "represented diverse malaria transmission settings". In the words of GSK Biologicals and PATH-MVI, the sites ((were chosen for their track record of world class clinical research, strong community relations and commitment to meeting the highest international ethical, medical, clinical and regulatory standards."

The malaria vaccine is a story that goes back to 1987, when GSK Biologicals (the Belgium-based vaccine division of the global pharmaceutical giant, GSK--headquartered in London) in collaboration with the US Army's Walter Reed Army Institute of Research (WRAIR) developed RTS, S as a vaccine candidate.

Dr Joe Cohen, who is currently GSK's vice president of Research and Development in charge of Emerging Diseases and HIV, is the co-inventor of RTS, S.

GSK Biologicals is the world's leading vaccine manufacturer. In 2008, it distributed to billion doses of vaccines to 176 countries across the globe. The company reveals that RTS, S was first tested in healthy adults in Belgium and the USA. It took it years of research before the vaccine was developed. "Phase One trials", however, were conducted among adults in The Gambia. In January 2001, with financial support from the Bill and Melinda Gates Foundation, GSK and the Programme for Appropriate Technology in Health-Malaria Vaccine Initiative (PATH-MVI) entered into a public-private partnership agreement to develop RTS, S for children in Africa,

[ILLUSTRATION OMITTED]

Phase two trials commenced in 2002 in Mozambique with 2,000 children in the study. The WHO notes that there are several malaria vaccines being studied but they are at least five to ten years behind RTS, S in their development."

In 2008, 16,000 children and infants in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania were earmarked for a massive vaccine trial. By January this year, according to PATHMVI, the entire project had enrolled 15,460 infants (between 6-12 weeks) and children between 5-17 months old.

[ILLUSTRATION OMITTED]

In November 2009, the RTS, S third phase trials were launched officially in Nairobi, Kenya.

Though the main stakeholders of RTS, S are GSK Biologicals and PATH-MVI, there are another 12 partners and 14 affiliate partners involved, mostly academic institutions.

It is important to note that the malaria vaccine research and development story involves a financial grail of immense proportions. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA 8, MLA 7, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Note: primary sources have slightly different requirements for citation. Please see these guidelines for more information.

Cited article

Hunt for Malaria Vaccine Raises a Storm: Malaria Kills More People in Africa Than HIV-Aids. Therefore Attempts to Produce a Vaccine against the Disease Should Normally Be Received with Joy. but No. the Trial Stages of a New Vaccine, RTS, S, Have Raised a Storm in Africa. Our Kenyan Correspondent, Wanjohi Kabukuru, Went to Find Out
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen
Items saved from this article
  • Highlights & Notes
  • Citations
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA 8, MLA 7, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Search by... Author
    Show... All Results Primary Sources Peer-reviewed

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.